Literature DB >> 12794528

Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia.

Matthias Kieslich1, Luciana Porto, Heinrich Lanfermann, Gert Jacobi, Dirk Schwabe, Hansjosef Böhles.   

Abstract

L-asparaginase is frequently used in combination therapy for the treatment of lymphoid malignancies. We report 5 children aged between 8 and 14 years with neurologic complications presenting with headache and seizures during the first three weeks of L-asparaginase treatment. Three patients had venous thrombosis, one presented a parenchymal hemorrhage, and one showed a peculiar encephalopathy with extended cortical and subcortical lesions suggesting a neurotoxic reaction. Decreased fibrinogen and antithrombin III levels were found. Early MRI is critical even in cases with mild neurologic symptoms. Diagnosis should be followed by early cessation of l-asparaginase application.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12794528     DOI: 10.1097/00043426-200306000-00011

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  15 in total

1.  Hyperintense vessel sign: isolated cortical venous thrombosis after L-asparaginase therapy.

Authors:  Krishnamoorthy Thamburaj; Arabinda Choudhary
Journal:  Pediatr Radiol       Date:  2009-03-03

2.  Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.

Authors:  Sarah M Kashanian; Noa G Holtzman; Ciera L Patzke; Jonathan Cornu; Alison Duffy; Madhurima Koka; Sandrine Niyongere; Vu H Duong; Maria R Baer; Jummai Apata; Farin Kamangar; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-07       Impact factor: 3.333

3.  The eukaryotic initiation factor 2 kinase GCN2 protects against hepatotoxicity during asparaginase treatment.

Authors:  Gabriel J Wilson; Piyawan Bunpo; Judy K Cundiff; Ronald C Wek; Tracy G Anthony
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-09-03       Impact factor: 4.310

Review 4.  Cerebral sinovenous thrombosis in children.

Authors:  Jessica Carpenter; Tammy Tsuchida
Journal:  Curr Neurol Neurosci Rep       Date:  2007-03       Impact factor: 5.081

Review 5.  Management of stroke in cancer.

Authors:  Lisa R Rogers
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

6.  Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments.

Authors:  Alessandra Erbetta; Andrea Salmaggi; Angelo Sghirlanzoni; Antonio Silvani; Paolo Potepan; Andrea Botturi; Elisa Ciceri; Maria Grazia Bruzzone
Journal:  Neurol Sci       Date:  2008-07-09       Impact factor: 3.307

Review 7.  Neurotoxicity of chemotherapeutic and biologic agents in children with cancer.

Authors:  Kevin C De Braganca; Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2008-03       Impact factor: 5.081

8.  Hemorrhagic and ischemic stroke in children with cancer.

Authors:  Corina Noje; Kenneth Cohen; Lori C Jordan
Journal:  Pediatr Neurol       Date:  2013-08-12       Impact factor: 3.372

9.  Suspected adverse reaction to compounded preparations prescribed for weight loss: two cases of cerebral venous thrombosis.

Authors:  Beatrice Mainoli; Mariana Carvalho Dias; Patricia Canhão; Mário Miguel Rosa
Journal:  BMJ Case Rep       Date:  2020-03-31

10.  Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia.

Authors:  A-Reum Han; Kihyun Kim; Jun Ho Jang; Won Seog Kim; Jin Seok Ahn; Chul Won Jung; Mark H Lee; Won Ki Kang
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.